Who qualifies for private weight loss injections in the UK?
Private treatment with a GPhC-registered pharmacy is accessible to a much broader group than NHS primary care. To be eligible for a private prescription of Mounjaro, Wegovy or other licensed weight loss injections, you generally need to meet ALL of the following:
– Be aged 18 or over
– Have a BMI of 30 or above, OR a BMI of 27 or above with at least one weight-related health condition (such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol, sleep apnoea, fatty liver disease, or polycystic ovary syndrome)
– Not be pregnant, breastfeeding, or planning pregnancy
– Not be taking another GLP-1 medication concurrently
– Have no contraindications to the specific medication (detailed below)
– Be willing to combine treatment with diet and lifestyle changes
A qualified prescriber reviews your responses and confirms suitability
before any prescription is issued. Treatment is never supplied without
this clinical review.
How does BMI adjustment work for different ethnic backgrounds?
BMI thresholds for weight loss injection eligibility are lowered by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. This reflects clinical evidence that people from these groups can experience higher metabolic risk at lower BMIs.
In practical terms:
– The standard NHS primary care threshold of BMI 40 becomes 37.5
– The standard private threshold of BMI 30 becomes 27.5
– The private-with-comorbidity threshold of BMI 27 becomes 24.5
– NICE’s clinical threshold of BMI 35 becomes 32.5
This adjustment is consistent across NHS and private prescribing pathways. If you are from one of these backgrounds, the adjusted threshold applies automatically to your eligibility assessment.
Who should NOT take weight loss injections?
Several groups should not be prescribed GLP-1 weight loss injections. You are not suitable for weight loss injection treatment if you:
– Are pregnant, breastfeeding or planning to become pregnant
– Are under 18 years of age
– Have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2)
– Have a history of pancreatitis
– Have severe gastrointestinal disease, including gastroparesis or severe inflammatory bowel conditions
– Have type 1 diabetes
– Are currently taking another GLP-1 medication such as Ozempic, Saxenda, Rybelsus or Victoza
– Have had a severe allergic reaction to tirzepatide, semaglutide or any of the ingredients
Some conditions require additional caution rather than outright exclusion. A qualified prescriber will weigh these factors during consultation and may recommend alternative treatments or additional monitoring.
How Live Well Weight Loss assesses eligibility
At Live Well Weight Loss, eligibility is assessed by a pharmacist independent prescriber registered with the General Pharmaceutical Council.
Our clinical review covers:
– Age verification — confirmation you are 18 or over
– BMI calculation — based on your reported height and weight
– Medical history — including any contraindications
– Current medications — to identify potential interactions
– Weight-related conditions — confirming any qualifying comorbidities
– Treatment expectations and lifestyle commitment
For new patients we may request supporting evidence such as identification, recent blood test results, or a summary from your GP where clinically appropriate. If treatment is not appropriate, we will explain why and, where possible, suggest alternative options.
Most clinical reviews are completed within one business day.
What changed in 2026?
Two notable changes affect UK access to weight loss injections in 2026:
April 2026 — NHS GP contract changes. NHS England moved tirzepatide prescribing into the 2026/27 GP contract as an optional QOF indicator.
GP practice participation is voluntary, and access varies by Integrated Care Board area.
June 2026 — Cohort 2 activation. From 23 June 2026, NHS England’s primary care eligibility expands to include patients with BMI 35–39.9 (32.5–37.4
with ethnic adjustment) plus four or more qualifying comorbidities.
Private pricing landscape. Following Eli Lilly’s September 2025 wholesale price increase for Mounjaro, private treatment costs rose across all UK
providers. Pricing variation reflects whether each provider has signed Lilly’s rebate programme and what consumables are included in the quoted cost.
We update this article as further changes to NHS commissioning, NICE guidance, or licensed indications come into effect.